Medical and Pharmaceutical Aerosols - Aerosols: Measurement, Dosimetry, and Health Effects - page 25

105. Dhand, R. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol.
Respiratory Care 47 , 1406 (2002).
106. Chan, K.N., Clay, M.M., and Silverman, M. Output characteristics of DeVilbiss No. 40 hand-held jet
nebulizers. European Respiratory Journal 3 , 1197-1201 (1990).
107. Smith, E.C., Denyer, J., and Kendrick, A.H. Comparison of twenty three nebulizer/compressor combina-
tions for domiciliary use. European Respiratory Journal 8 , 1214-1221 (1995).
108. Weber, A. et al. Effect of nebulizer type and antibiotic concentration on device performance. Pediatric
Pulmonology 23 , 249-260 (1997).
109. Montgomery, A.B. Aerosolized pentamidine for treatment and prophylaxis of Pneumocystis carinii pneu-
monia in patients with acquired immunodeiciency syndrome. In: Pharmaceutical Inhalation Aerosol
Technology , 2nd Edn., Hickey, A.J., Ed. Marcel Dekker: New York, pp. 459-472 (2004).
110. Niven, R.W. Modulated drug therapy with inhalation aerosols. In: Hickey, A.J., ed. Pharmaceutical
Inhalation Aerosol Technology . Marcel Dekker: New York, Vol. 54, pp. 321-359 (1992).
111. Collins, N. Nebulizer therapy in cystic ibrosis: An overview. Journal of the Royal Society of Medicine
102 , S11-S17 (2009).
112. Hubert, D. et al. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow ® rapid
nebulizer in cystic ibrosis. Journal of Cystic Fibrosis 8 , 332-337 (2009).
113. Falagas, M.E., Michalopoulos, A., and Metaxas, E.I. Pulmonary drug delivery systems for antimicrobial
agents: Facts and myths. International Journal of Antimicrobial Agents 35 , 101-106 (2010).
114. Garcia-Contreras, L. and Hickey, A.J. Pharmaceutical and biotechnological aerosols for cystic ibrosis
therapy. Advanced Drug Delivery Reviews 54 , 1491-1504 (2002).
115. Jones, L.D., McGlynn, P., Bovet, L., and Hickey, A.J. Analysis and stability of pharmaceutical aerosols.
Pharmaceutical Technology 24 , 40-54 (2000).
116. Summers, Q.A., Nesbit, M.R., Levin, R., and Holgate, S.T. A non-bronchoconstrictor, bacteriostatic pre-
servative for nebuliser solutions. British Journal of Clinical Pharmacology 31 , 204-206 (1991).
117. Rocchiccioli, K. and Pickering, C. Air-low obstruction induced by ultrasonically nebulized water—The
underlying mechanism. Thorax 39 , 710-710 (1984).
118. Borland, C., Chamberlain, A., Barber, B., and Higenbottam, T. The effect of ultrasonically nebulized
distilled water on air-low obstruction, regional ventilation and lung epithelial permeability in asthma.
Thorax 39 , 240-240 (1984).
119. Atkins, P., Barker, P.N., and Matiesen, D. The design and development of inhalation drug delivery
systems. In: Pharmaceutical Inhalation Aerosol Technology , 2nd Edn., Hickey, A.J., Ed., Marcel
Dekker: New York, pp. 258-285 (1992).
120. Cameron, D., Clay, M., and Silverman, M. Evaluation of nebulizers for use in neonatal ventilator circuits.
Critical Care Medicine 18 , 866-870 (1990).
121. Tiano, S.L. and Dalby, R.N. Comparison of a respiratory suspension aerosolized by an air-jet and an
ultrasonic nebulizer. Pharmaceutical Development and Technology 1 , 261-268 (1996).
122. Niven, R.W., Carvajal, T.M., and Schreier, H. Nebulization of liposomes. III. The effects of operating
conditions and local environment. Pharmaceutical Research 9 , 515-520 (1992).
123. Niven, R.W. and Schreier, H. Nebulization of liposomes. I. Effects of lipid composition. Pharmaceutical
Research 7 , 1127-1133 (1990).
124. Niven, R.W., Speer, M., and Schreier, H. Nebulization of liposomes. II. The effects of size and modeling
of solute release proiles. Pharmaceutical Research 8 , 217-221 (1991).
125. Lange, C.F., Hancock, R.E.W., Samuel, J., and Finlay, W.H. In vitro aerosol delivery and regional airway
surface liquid concentration of a liposomal cationic peptide. Journal of Pharmaceutical Sciences 90 ,
1647-1657 (2001).
126. Zaru, M. et al. Rifampicin-loaded liposomes for the passive targeting to alveolar macrophages: In vitro
and in vivo evaluation. Journal of Liposome Research 19 , 68-76 (2009).
127. Li, Z. et al. Characterization of nebulized liposomal amikacin (Arikace™) as a function of droplet size.
Journal of Aerosol Medicine and Pulmonary Drug Delivery 21 , 245-253 (2008).
128. Desai, T.R. and Finlay, W.H. Nebulization of niosomal all-trans-retinoic acid: An inexpensive alternative
to conventional liposomes. International Journal of Pharmaceutics 241 , 311-317 (2002).
129. Ip, A.Y., Arakawa, T., Silvers, H., Ransone, C.M., and Niven, R.W. Stability of recombinant consensus
interferon to air-jet and ultrasonic nebulization. Journal of Pharmaceutical Sciences 84 , 1210-1214 (1995).
130. Gale, A. Drug degeneration during ultrasonic nebulization. Journal of Aerosol Science 16 , 265 (1985).
131. Kosugi, T., Nakamura, M., Noguchi, S., and Huang, G.W. Effect of ultrasonic nebulization of miraclid ®
on the proteolytic activity in tracheobronchial secretions of rats. The Laryngoscope 99 , 1281-1285
(1989).